Researchers in the Division of Endocrinology, Diabetes and Hypertension at Brigham and Women’s Hospital found thyroid-stimulating immunoglobulin bioassay (TSI) and thyrotropin-binding inhibitory immunoglobulin assay (TBII) performed similarly for discriminating Graves’ disease from other causes of thyrotoxicosis.

Colleagues from the Brigham’s Center for Adrenal Disorders assessed the efficacy of aldosterone antagonism with a mineralocorticoid receptor (MR) antagonist versus placebo in patients with primary hyperparathyroidism (P-HPT). They provide evidence that MR antagonists have no meaningful role in P‐HPT treatment.

Based on findings from a novel mouse model, researchers at Brigham and Women’s Hospital led by Ursula B. Kaiser, MD, suggest that genetic variants resulting in increased MKRN3 expression may be a previously unrecognized cause of delayed puberty.

Sylvia Kehlenbrink, MD, endocrinologist and director of Global Endocrinology at Brigham and Women’s Hospital, and colleagues outline challenges and possible solutions for providing diabetes care during acute and prolonged humanitarian crises.

Lead author Meryl S. LeBoff, MD, discusses the new Bone Health and Osteoporosis Foundation’s “Clinician’s Guide to Prevention and Treatment of Osteoporosis,” along with the urgency of enhancing the prevention, risk management, diagnosis, and treatment of osteoporosis in postmenopausal women and men aged 50+ years.

To address conflicting evidence, Meryl S. LeBoff, MD, JoAnn E. Manson, MD, PhD, MPH, and colleagues conducted an ancillary analysis of the Vitamin D and Omega-3 Trial (VITAL). They found vitamin D did not affect fracture risk in the general population.